As a consequence, carriers of the alternative allele, those with lower risk of CHD, have a 2-fold increase in the circulating levels of soluble IL-6R and reduced downstream IL-6 signaling as demonstrated by the lower levels of hsCRP and fibrinogen. The gene discussed is IL6; the disease is coronary artery disorder.